Studying brain energy and glutamate levels in schizophrenia using brain scans
Compares brain chemistry and activity scans in people with schizophrenia and healthy volunteers.
Key facts
- Who runs it
- King's College London
- Where
- London, United KingdomSee the site
- Trial code
- Registry title
- Energetics and Glutamate in Schizophrenia
- Status
- Recruiting
- People taking part
- 75 people, planned
- Started
- 4 Mar 2024
- Expected to end
- 1 Dec 2028
- Type of study
- Observational, 3 groups
- Treatments tested
- MRI scan
- PET-MR scan
- Record updated
- 5 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers and adults with schizophrenia who take certain antipsychotic medicines. It compares brain chemistry and energy use using MRI and PET-MRI scans.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Three groups: healthy volunteers with no psychiatric illness; people with schizophrenia (ICD-11 F20) in remission with no relapse in the past 6 months; people with treatment-resistant schizophrenia (PANSS total score above 70, SOFAS below 60).
- Earlier treatment
- People with schizophrenia must take one or more listed antipsychotics (olanzapine, risperidone, quetiapine, amisulpride, aripiprazole, paliperidone; clozapine for the treatment-resistant group) and take them as prescribed. Treatment-resistant group: at least two earlier antipsychotic trials of at least 6 weeks each.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Diabetes or past use of antidiabetic medicine
- Cannot have a 7 Tesla MRI (for example metal or electronic implants) or has severe claustrophobia
- Total radiation exposure of 10mSv or more within 12 months, including this study
- Head injury with loss of consciousness for more than 5 minutes
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Healthy volunteer group:
- No history of psychiatric illness, as assessed on the Mini neuropsychiatric Interview (MINI); Treatment responsive schizophrenia group:
- Meeting ICD-11 criteria for schizophrenia (F20)
- Meeting symptomatic consensus criteria for remission, defined as scores of mild or less on items P1, P2, P3, N1, N4, N6, G5 and G9 of the PANSS and no history of symptomatic relapse in the past 6 months
- Currently receiving one or more of the following antipsychotic medications: Olanzapine; Risperidone; Quetiapine; Amisulpride; Aripiprazole; Paliperidone
- Antipsychotic adherent, defined as having a score of >=moderate adherence on the Kemp scale; Treatment-resistant schizophrenia group:
- Meeting ICD-11 criteria for schizophrenia (F20)
- Meeting modified consensus criteria for treatment resistance, including history of at least two antipsychotic treatment trials each lasting ≥6 weeks at a dose of ≥400mg chlorpromazine equivalents
- Total PANSS total score > 70
- Moderate functional impairment (<60 on the SOFAS)
- Currently receiving one or more of the following antipsychotic medications: Clozapine; Olanzapine; Risperidone; Quetiapine; Amisulpride; Aripiprazole; Paliperidone
- Antipsychotic adherent, defined as having a score of >=moderate adherence on the Kemp scale
Who cannot take part
- Severe claustrophobia prohibiting participation on PET or MRI 5. Body size above the comfortable limits for the MRI scanner. 6. Previous participation in research or clinical procedure/s involving ionising radiation, which, including the current study, would result in total radiation exposure >=10mSv within 12 months 7. History of head injury resulting in loss of consciousness for > 5 minutes 8. Meeting ICD-11 criteria for organic mental disorder (F00-F09) 9. Meeting ICD-11 criteria for mental and behavioural disorders due to psychoactive substance use (F10-F19) 10. With exclusion of nicotine or cannabis, meeting ICD-11 criteria for psychoactive substance dependence 11. Participation in clinical trial investigating any pharmacological agent other than a licensed antipsychotic compound in the last month
- Diabetes or history of taking an antidiabetic medication 3. Presence of contraindication to MRI at 7 Tesla, including metallic or electronic implants and dental wires
- All participants:
- Pregnancy or breastfeeding
- Lacking in mental capacity to provide informed consent to study participation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United Kingdom
- South London and the Maudsley NHS Foundation TrustLondon, United KingdomContact: Alice Egerton, PhDTaking people
About the trial
What the trial wants to find out
The goal of this case-control study is to compare brain glutamate, glucose utilisation, lactate production and brain activity in healthy volunteers and people with a diagnosis of schizophrenia.
Read full original descriptionShow less
It investigates the following main questions:
Whether, compared to healthy volunteers, participants with schizophrenia show:
1. reduction in brain glucose utilisation 2. increased brain lactate 3. greater variability in brain glutamate
Participants will be asked to have a screening visit, a MRI brain scan and a PET-MRI brain scan.
The 3 groups in the trial
- Healthy volunteers
Treatment: MRI scan and PET-MR scan
- Schizophrenia - remission
Treatment: MRI scan and PET-MR scan
- Treatment resistant schizophrenia
Treatment: MRI scan and PET-MR scan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Energetics and Glutamate in Schizophrenia
- Plain-language title
- Studying brain energy and glutamate levels in schizophrenia using brain scansGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06236048, who can take part
- Record updated
- 5 September 2025